Kallyope Executive Summary: A Journey Towards Strategic Partnerships and Exploring an Untapped Market

Julia Lisboa, Caroline Marshall, Jerry Ma, Erick Yu, Sophia Lin

Healthcare Management, Design, and Strategy

Professors Chan, Tollman, Rustgi

12/8/25

Our project centered on a strategic question for Kallyope: How can the company best monetize a novel dataset focused on the gut–brain axis? To address this, our team first evaluated the dataset’s scientific quality, its level of novelty, and its potential value compared with other data-driven transactions in the biotech sector. From this assessment, we identified three potential monetization pathways:

1. Continue business as usual and continue to use the dataset internally.
2. Sell the dataset in a one-time transaction, generating immediate revenue but forgoing any future upside.
3. Form a strategic partnership that includes upfront payments and downstream royalties tied to discoveries enabled by the dataset.

Based on Kallyope’s prior success with partnership structures and broader industry precedent, we determined that a strategic partnership model offers the highest long-term value.

To guide this recommendation, we conducted benchmarking across three relevant industries: pharmaceuticals, medical devices/diagnostics, and AI-powered drug discovery. For each sector, we evaluated prior deal structures, strategic alignment, value capture potential, internal capabilities required, and expected timelines to asset development.

Within the pharmaceutical sector, we identified COMPANY as a particularly strong candidate given its focus on the gut–brain axis and close scientific alignment with Kallyope’s dataset. Should Kallyope prioritize pharmaceutical partnerships, COMPANY stands out as a compelling target.

In the medical device/diagnostics sector, our analysis highlighted COMPANY as the most strategically aligned partner due to its capabilities and focus areas. However, since Kallyope has limited visibility in this industry, we recommend first building awareness through scientific publications, white papers, and targeted thought-leadership marketing to stimulate market interest.

For AI-enabled drug discovery companies, we found the space to be highly saturated with data, reducing the relative uniqueness of Kallyope’s dataset and limiting the likelihood of securing a successful partnership.

Based on these insights, we recommend a two-tiered strategy for Kallyope:

1. Pursue strategic partnerships with small, scientifically aligned pharmaceutical companies—particularly those focused on metabolic and gut–brain pathways.
2. Test and develop interest within the medical device/diagnostics sector through increased scientific visibility and marketing efforts, using this as a complementary secondary pathway.

This strategic approach positions Kallyope to capture both near-term revenue and long-term royalty-based upside while maximizing the value embedded in its unique gut–brain axis dataset.